Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study

Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study

Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among immunocompromised patients with underlying malignancies and prior transplants. FDA approved Isavuconazole as a primary therapy for Invasive Aspergillosis (IA) and Mucormycosis. This study aims to compare the real-wo...

Full description

Bibliographic Details
Main Authors: Marjorie Vieira Batista, Maria Piedad Ussetti, Ying Jiang, Dionysios Neofytos, Anita Cassoli Cortez, Diego Feriani, Jayr Schmidt-Filho, Ivan Leonardo Avelino França-Silva, Issam Raad, Ray Hachem
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Journal of Fungi
Subjects:
IFI
SCT
disparities
triazoles
isavuconazole
voriconazole
Online Access:https://www.mdpi.com/2309-608X/9/2/166

Internet

https://www.mdpi.com/2309-608X/9/2/166

Similar Items